



Company Announcement

Thursday 20th November 2008
Melbourne, Australia

Appendix 3Y – Change in Director’s Interest Notice

The aforementioned Appendix relates to:

- * the on-market purchase by Director Mr Jack Wood of 100,000 ordinary shares in Clinuvel, and
- * the issue of 350,000 unlisted options to Mr Jack Wood, approved by shareholders at the Annual General Meeting on 13 November.

- End -

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company with offices in San Francisco and Zürich developing its photo-protective drug afamelanotide as a preventative treatment for a range of UV-related skin disorders as well as cancer related treatments.

Clinuvel's five UV-light related indications are:

Indication	Description	Clinical Trial Status
Erythropoietic Protoporphyrin (EPP)	Absolute sun intolerance	Phase III trials started April 2007
Polymorphic Light Eruption (PLE / PMLE)	Severe sun poisoning	Phase III trials started May 2007
Actinic Keratosis (AK) and Squamous Cell Carcinoma (SCC) in Organ Transplant Recipients (OTR)	OTRs have an absolute dramatic risk to skin cancers	Phase II trials started October 2007
Solar Urticaria (SU)	Acute anaphylactic reaction to sun	Phase II trials started June 2008
Photodynamic Therapy (PDT) systemic	Phototoxicity associated with cancer treatment (oesophagus, gall bladder)	Phase II trials started September 2008

Phase I and II human clinical trials using afamelanotide have demonstrated that the drug is well tolerated and no significant safety concerns have been identified to date.

Following successful conclusion of the development program, Clinuvel will work closely with global regulators to facilitate marketing approval of afamelanotide.

For more information contact:

Darren Keamy
Company Secretary
Clinuvel Pharmaceuticals Limited
Tel: +61 3 9660 4900
investorrelations@clinuvel.com

Clinuvel is an Australian biopharmaceutical company focussed on developing its photo-protective drug, afamelanotide (CUV1647), for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for CUV1647 can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development programme for afamelanotide is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place

**Level 11 / 330 Collins Street
Melbourne, Victoria 3000
Australia**

**T +61 3 9660 4900
F +61 3 9660 4999**

www.clinuvel.com

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Clinuvel Pharmaceuticals Ltd
ABN	88 089 644 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lawrence John (Jack) Wood
Date of last notice	14 July 2008

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct Interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	17 November 2008 (Ordinary Shares) 18 November 2008 (Unlisted Options)
No. of securities held prior to change	Nil Ordinary Shares Nil Unlisted Options
Class	Ordinary Shares (fully paid) & Unlisted Options
Number acquired	100,000 Ordinary Shares 350,000 Unlisted Options
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$25,025 (Ordinary Shares) \$Nil (Unlisted Options)
No. of securities held after change	100,000 Ordinary Shares 350,000 Unlisted Options

+ See chapter 19 for defined terms.

<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Ordinary Shares - On-market trade Unlisted Options – Issue of options under Employee Option Plan and approved by shareholders in AGM 13 November 2008</p>
---	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
<p>No. and class of securities to which interest related prior to change</p> <p><small>Note: Details are only required for a contract in relation to which the interest has changed</small></p>	
Interest acquired	
Interest disposed	
<p>Value/Consideration</p> <p><small>Note: If consideration is non-cash, provide details and an estimated valuation</small></p>	
Interest after change	

+ See chapter 19 for defined terms.